• TUICHIEV Laziz Nadirovich
  • TAJIEVA Nigora Ubaydullaevna
  • YARMUKHAMEDOVA Nargiza Anvarovna
  • SAMIBAYEVA Umida Khurshidovna
  • IMAMOVA Ilmira Abdullaevna


COVID-19, SARS-CoV-2 virus, etiology, epidemiology


The purpose of the study: Study in detail the etiological and epidemiological aspects of COVID- 19, which will make it possible to understand the temporal transformation of this infectious disease. This will allow, based on the literature review data, to expand and correct the view of epidemiologists and practicing physicians on this infection.

  1. The study of the etiological and epidemiological properties of COVID-19 using molecular genetic research methods continues to indicate the discovery of new ways of interactions of coronaviruses with the human body, this will improve new approaches to the prevention of this
  2. The transformation of coronavirus infection has been established: registration of mild cases until 2002, registration of SARS-Cov in 2002, registration of MERS-Cov in 2012, which caused epidemics with the development of severe forms of infection and nosocomial outbreaks, in 2019 SARS-CoV-2 which caused a severe acute respiratory syndrome with high mortality. At the present stage, there is a gradual decrease in the aggression of the virus.
  3. The main epidemiological and clinical criteria necessary for diagnosing COVID-19 in the initial period of a pandemic have been
  4. The main method of preventing severe forms of COVID-19 is vaccine prevention with guaranteed safety before widespread


Попович Ю.Г., Рахимова Р.Ж., Ахметжанова Д.О. COVID 19 - Новая инфекция XXI века // Наука и здравоохранение. 2020. - №4.

World Health Organization et al. Coronavirus disease 2019 (COVID-19): situation report, 2020.- С.73.

Coronavirus N. situation reports-World Health Organization (WHO), 2019 Novel Coronavirus (2019-nCoV) in the US //US Centers for Disease Control and Prevention (CDC), symptoms of Novel Coronavirus (2019-nCoV)–CDC, china Travel Advisory-US State Department. Accessed. – 2020. – Т. 31.

WHO Coronavirus (COVID-19) Dashboard [онлайновая база данных]. Женева: Всемирная организация здравоохранения; 2021 г. (

Li Q. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia //New England journal of medicine. - 2020.

Zhang C. et al. Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV- 1 //Journal of proteome research. - 2020. - Т. 19. - №. 4. - С. 1351-1360.

Национальный институт инфекционных заболеваний, Южная Африка. Часто задаваемые вопросы о мутировавшей линии B.1.1.529 SARS-CoV-2 в Южной Африке. cov-2-lineage-in-south-africa/ (по состоянию на ноябрь 29, 2021)

Европейский центр профилактики и контроля заболеваний. Краткий обзор оценки угрозы: последствия появления и распространения SARS-CoV-2 B.1.1.529 вариант концерна (Omicron) для ЕС/ЕЭЗ. assessment-brief-emergence-sars-cov-2-variant-b.1.1.529 (по состоянию на 29 ноября 2021 г.)

Всемирная организация здоровья. Усиление ответа на вариант Omicron SARS-CoV- 2. technical-brief-and-priority-actions-for-member-states (по состоянию на 29 ноября 2021 г.)

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020 Apr; 5(4):536-544. doi: 10.1038/s41564-020- 0695-z. Epub 2020 Mar 2. PMID: 32123347; PMCID: PMC7095448.

Саидалиев С. С., Мирзабаев Д. С., Мадаминов М. М. Опыт борьбы с коронавирусной инфекцией в Республике Узбекистан //Проблемы особо опасных инфекций. - 2020. - №. 2. - С. 138-140.

Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19): People at Higher Risk. Centers for Disease Control and Prevention. Available at ncov/specific-groups/high-risk-complications.html. March 8, 2020; Accessed: March 9, 2.

Kolavita F., Lapa D., Carletti F. et al. Isolation of SARS-CoV-2 from the ocular secretions of a patient with COVID-19 in Italy with prolonged detection of viral RNA. Ann Intern Med. 2020.-№173.-С.242.

Попова А. Ю. Руженцова Т.А., Хавкина Д.А., Туйчиев Л.Н., Ахмедова М.Д. и др. Опыт международного сотрудничества по организации учреждениями здравоохранения противоэпидемических мероприятий в условиях пандемии COVID-19 в Республике Узбекистан. Проблемы особо опасных инфекций. 2021;(3):122-128.

Плутницкий А.Н. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17. 14.2.2022.

He X., Lau EHY, Wu P., Deng X., Wang J., Hao X., Lau Y.C., Wong J.Y., Guan Y., Tan X., Mo X., Chen Y., Liao B., Chen W., Hu F., Zhang Q., Zhong M., Wu Y., Zhao L., Zhang F., Cowling B.J., Li F., Leung G.M. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 May.-№26(5).-С.672-675.

Jones T.C., Biele G., Mühlemann B., Veith T., Schneider J., Beheim-Schwarzbach J., Bleicker T., Tesch J., Schmidt M.L., Sander L.E., Kurth F., Menzel P., Schwarzer R., Zuchowski M., Hofmann J., Krumbholz A., Stein A., Edelmann A., Corman V.M., Drosten C. Estimating infectiousness throughout SARS-CoV-2 infection course. Science. 2021 Jul 9.- №373(6551):eabi5273. doi: 10.1126/science.abi5273. Epub 2021 May 25. PMID: 34035154; PMCID: PMC9267347.

Ke R., Martinez P.P., Smith R.L. et al. Daily longitudinal sampling of SARS-CoV-2 infection reveals a significant heterogeneity of infection. Nat microbiol 2022; 7:640

Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. PMID: 32091533.

de Wilde A.H., Snijder E.J., Kikkert M., van Hemert M.J. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018; 419:1-42. doi: 10.1007/82_2017_25. PMID: 28643204; PMCID: PMC7119980.

Rathmann W., Kuss O., Kostev K. Incidence of newly diagnosed diabetes after Covid-19. Diabetologia. 2022 Jun;65(6):949-954. doi: 10.1007/s00125-022-05670-0. Epub 2022 Mar 16. PMID: 35292829; PMCID: PMC8923743.

Zou L., Ruan F., Huang M., Liang L., Huang H., Hong Z., et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020 Feb 19. [Medline].

Mercatelli D., Giorgi F.M. Geographic and genomic distribution of SARS-CoV-2 mutations //Frontiers in microbiology. - 2020. - Т. 11. - С. 1800.

Rambaut A. et al. Louis du Plessis, and Oliver G //Pybus. 2020b.“A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology.” Nature Microbiology. - 2020. - Т. 5. - №. 11. - С. 1403-7.

Phylogenetic Assignment of Named Global Outbreak LI Neages (PANGOLIN) updated 2020.

Никонова А.А. и др. Генетическое разнообразие и эволюция биологических свойств коронавируса SARS-COV-2 в условиях глобального распространения //Acta Naturae - 2021. - Т. 13. - №. 3. - С. 77-89.

Wang F., Huang S., Gao R., Zhou Y., Lai C., Li Z., Xian W., Qian X., Li Z., Huang Y., Tang Q., Liu P., Chen R., Liu R., Li X., Tong X., Zhou X., Bai Y., Duan G., Zhang T., Xu X., Wang J., Yang H., Liu S., He Q., Jin X., Liu L. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 2020 Nov 10;6(1):83. doi: 10.1038/s41421-020-00231-4. PMID: 33298875; PMCID: PMC7653987.

Kaser A. Genetic risk of severe Covid-19 //New Enland Journal of Medicine. - 2020. - Т. 383. - №. 16.- С. 1590-1591.

Hou Y., Zhao J., Martin W., Kallianpur A., Chung M.K., Jehi L., Sharifi N., Erzurum S., Eng C., Cheng F. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020 Jul 15; 18(1):216. doi: 10.1186/s12916-020-01673- z. PMID: 32664879; PMCID: PMC7360473.

Вологжанин Д.А. и др. Генетика COVID-19 //Клиническая практика.–2021.–Т. 12.– №.1.–С 41-52.

Meng B, et al. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021 Jun 29; 35(13):109292. doi: 10.1016/j.celrep.2021.109292. Epub 2021 Jun 8. PMID: 34166617; PMCID: PMC8185188.

Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9241-9243. doi: 10.1073/pnas.2004999117. Epub 2020 Apr 8. PMID: 32269081; PMCID: PMC7196762.

Yang X. et al. Genetic cluster analysis of SARS-CoV-2 and the identification of those responsible for the major outbreaks in various countries //Emerging microbes & infections. - 2020. - Т. 9. - №. 1. - С. 1287-1299.

Centers for Disease Control and Prevention, CDC. About variants of the virus that causes COVID-19. - Atlanta (USA) CDC, 2021.

Wang W. B. et al. E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies //Journal of Molecular Graphics and Modelling. - 2021. - Т. 109. - С. 108035.

Gladkikh A. et al. Characterization of a novel SARS-CoV-2 genetic variant with distinct spike protein mutations //Viruses. - 2021. - Т. 13. - №. 6. - С. 1029.

Klink G. V. et al. The CoRGI (Coronavirus Russian Genetic Initiative) Consortium. 2021. “Spread of Endemic SARS-CoV-2 Lineages in Russia.” bioRxiv //medRxiv.

Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications //Genomics. - 2020. - Т. 112. - №. 5. - С. 3588-3596.66. Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Crit Care. 2019; 23(1):303. doi: 10.1186/s13054-019- 2566-7.

Centers for Disease Control and Prevention. New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection. - 2021.

Всемирная организация здравоохранения. Лекарственная терапия при COVID-19. Вариативные рекомендации. - 2022. - 125 с.

Crist С. Paxlovid Reduces Risk of COVID Death by 79% in Older Adults: Study // Medscape. - 2022.

Hajibeygi, R., Mirghazanfari, S. M., Pahlavani, N., Jalil, A. T., Alshahrani, S. H., Rizaev, J. A., Yekta, N. H. (2022). Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial. European Journal of Integrative Medicine, 102179.

Зейнитдинова, З. А., РИЗАЕВ, Ж. А., & Орипов, Ф. С. (2022). Степень цитологического поражения эпителия слизистой оболочки щеки при COVID-19. ЖУРНАЛ БИОМЕДИЦИНЫ И ПРАКТИКИ, 7(2).

Umirzakov Zokir, Rizaev Jasur, UMIROV Safar. The phenomenon of the epidemic covid-19 process and their leading determinants. Journal of Biomedicine and Practice. 2021, vol. 6, issue 6, pp. 286-295

Ризаев, ж. А., Кушаков, Б. Ж., Рустамова, Д. А. (2022). Проявления коронавирусной инфекции SARS-COV-2 в полости рта. Журнал биомедицины и практики, 7(2).

Умирзаков, З., Ризаев, Ж., Умиров, С., & Рустамова, Д. (2022). ОРГАНИЗАЦИЯ МЕДИЦИНСКИХ УСЛУГ В ЭПИДЕМИЧЕСКОМ ЦЕНТРЕ COVID-19. Журнал стоматологии и краниофациальных исследований, 2(3), 67–73.